Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma

Author： Opoku-Ansah John Ibarra-Rivera Tannya R. Pirrung Michael C. Bachmann André S.

Publisher： Informa Healthcare

ISSN： 1388-0209

Source： Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol.50, Iss.1, 2012-01, pp. : 25-29

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A review of the proteasome inhibitor bortezomib in multiple myeloma

By Richardson Paul G

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 6, 2004-06 ,pp. : 1321-1331

Informa Healthcare

Access to resources Recommend Favorite

Proteasome Inhibitors and Modulators of Angiogenesis in Multiple Myeloma

Current Medicinal Chemistry, Vol. 18, Iss. 34, 2011-12 ,pp. : 5185-5195

Bentham Science Publishers

Access to resources Recommend Favorite

Proteasome Inhibitors in the Clinical Setting: Benefits and Strategies to Overcome Multiple Myeloma Resistance to Proteasome Inhibitors

By Cheriyath Venugopalan Jacobs Barbara S.

Drugs in R&D, Vol. 8, Iss. 1, 2007-01 ,pp. : 1-12

Adis International

Access to resources Recommend Favorite

Multiple myeloma

By Samson Diana Singer Charles

Clinical Medicine, Vol. 1, Iss. 5, 2001-09 ,pp. : 365-370

Royal College Of Physicians

Access to resources Recommend Favorite

Radioligand binding affinity and biological activity of the enantiomers of a chiral melatonin analogue

By Sugden D. Davies D.J. Garratt P.J. Jones R. Vonhoff S.

European Journal of Pharmacology, Vol. 287, Iss. 3, 1995-12 ,pp. : 239-243

Elsevier

Access to resources Recommend Favorite